Skip to main content
SpringerLink
Log in

The effect of long term and high dose interferon treatment in Chronic hepatitis C

  • Article
  • Published:
Pathology & Oncology Research

Abstract

The results of 43 interferon treatments of 35 patients (23 male, 12 female) are reported. The duration of the treatment was 6–18 months, the dose of interferon was 3x3-5 MU weekly. Complete response (HCV RNA became negative) was found in 11, relapse was observed in 3 patients. Partial response (transaminase levels became normal, or less than twice normal value, but patients remained HCV RNA positive) occurred in 23 cases, relapse was obeserved in 16. The therapy had no effect in 9 cases. The higher dose and longer term interferon therapy resulted in a higher rate of response to the treatment and a reduction in the number of relapses.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

IFN:

deinterferon

HCV:

hepatitis C virus

References

  1. Benelux Multicentre Trial Study Group: Benelux multicentre trial of alpha interferon treatment for chronic hepatitis C: standard v. high dose treatment monitored by biochemical and virological markers (interim analysis) Gut 34(Suppl): S119-S120, 1993.

  2. Bosch O, Tapia L, Quiroga JA and Carreno V.: An escalating dose regime of recombinant interferon-alpha 2A in the treatment of chronic hepatitis C. J Hepatol 17:146–149, 1993.

    Article  PubMed  CAS  Google Scholar 

  3. Camps J, Castilla A, Ruiz J, Civiera MP and Prieto J: Randomised trial of lymphoblastoid alpha-interferon in chronic hepatitis C. Effects on inflammation. fibrogenesis and viraemia. J Hepatol 17:390–396, 1993.

    Article  PubMed  CAS  Google Scholar 

  4. Chemello L., Bonetti P, Cavalletto L, Talato F, Donadon V, Casarin P, Belussi F, Frezza M, Noventa F, Pontisso P, Benvegnu L, Casarin C,Alberti A and the TriVeneto Viral Hepatitis Group: Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. Hepatology 22:700–706, 1995.

    PubMed  CAS  Google Scholar 

  5. De Bac C, Grimaldi F, Clementi C, Duca F, Livoli D and Taliani G: Efficacy of different regimens of interferon alfa-2b treatment in chronic hepatitis C Gut 34(Suppl):S135 1993.

    Article  Google Scholar 

  6. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, and Scheuer PJ: Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 19:1513–1520. 1994.

    PubMed  CAS  Google Scholar 

  7. Di Bisceglie A, Martin P, Kassianides C, Lisker-Melman M, Murray LWJ, Goodman Z and Banks S: Recombinant interferon alpha therapy for chronic hepatitis C: a randomized, double-blind, placebo-controlled trial. N Engl J Med 321:1506–1510, 1989.

    PubMed  Google Scholar 

  8. Goodman ZD, and Ishak KG: Histopathology of hepatitis C virus infection. Seminars in Liver Diseases 15:70–81. 1995.

    CAS  Google Scholar 

  9. Hoofnagle JH, Di Bisceglie AM and Shindo M: Antiviral therapy of hepatitis C present and future. J Hepatol 17(Suppl. 3): 130–136, 1993.

    Article  Google Scholar 

  10. Horváth G, Tolvaj Gy and Dávid K: The prevalence of hepatitis B, C and D virus infection in chronic liver diseases Orv Hetil 133:2475–2480, 1992.

    PubMed  Google Scholar 

  11. Iino S, Hino K, Kuroki T, Suzuki H, Yamamoto S, Kondo T and Nashida Y: Treatment of chronic hepatitis C with high dose alpha-interferon-2b: a multicenter study. Dig Dis Sci 38:612–618, 1993.

    Article  PubMed  CAS  Google Scholar 

  12. Iino S: High dose interferon treatment in chronic hepatitis C. Gut 34(Suppl):S114-S118. 1993.

    Article  Google Scholar 

  13. Ishak KG, Baptista A, Bianchi L, Callea F De Groote J, Gudat F Denk H, Desmet V Korb G, MacSween RNM, Phillips MJ, Bortmann BG, Paulsen H, Scheuer PJ, Scmid M, Thaler H: Histological grading and staging of chronic hepatitis. J Hepatol 22:696–699, 1995.

    Article  PubMed  CAS  Google Scholar 

  14. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kuplowitz N, Kiernan TW and Wollman J: Formulation on aplication of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1:431–435. 1981.

    Article  PubMed  CAS  Google Scholar 

  15. Métreau JM and French Group for the study of NANB/C chronic hepatitis treatment: Results of long term interferon treatment in non-A non-B/C chronic active hepatitis Gut 34(Suppl): S112-S113, 1993.

    Article  Google Scholar 

  16. Okada S-I, Akahane Y, Suzuki H, Okamoto H and Mishiro S: The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients Hepatology 16:619–624, 1992.

    Article  PubMed  CAS  Google Scholar 

  17. Pár A, Paál M, Gógl Á, Gervain J, Szekeres J, Sipos J, Beró T, Hütter E, Berencsi G, Kádas I, Hegedüs G, Brasch G and Szabolcsi I: Clinical and immunological features of chronic hepatitis C and the effect of interferon alpha treatment. Orv Hetil 136:9–18, 1995.

    PubMed  Google Scholar 

  18. Pár A: Advances in the non-A. non-B hepatitis research: hepatitis C virus. A multicenter study Orv Hetil 131:2295–2298. 1990.

    Google Scholar 

  19. Pár A: Prevalence of antibody to hepatitis C virus (HCV) in blood donors, high risk groups and liver diseases in Hungary Orv.Hetil. 132:955–959. 1991.

    PubMed  Google Scholar 

  20. Reichard O, Foberg U, Frydén A, Mattsson L, Norkrans G, Sönnerborg A, Wejstal R, Zhi-Bing Y and Weiland O: High sustained response rate and clearance of viraemia in chronic hepatitis C after treatment with interferon alpha 2b for 60 weeks Hepatology 19:280–285, 1994.

    Article  PubMed  CAS  Google Scholar 

  21. Rumi MG, Del Ninno E, Parravicini ML, Romeo R, Soffredini R, Donato MF Zahm F, andColombo M: Long-term titrated recombinant interferon alpha 2a in chronic hepatitis C: a randomized controlled trial. J Viral Hepatitis 2:73–76, 1995.

    Article  CAS  Google Scholar 

  22. Sáez-Rouyela F, Porres JC, Moreno A, Castillo I, Martinez G, Galiana F and Carreno V: High doses of recombinant alpha interferon or gamma interferon for chronic hepatitis C: a randomized, controlled trial. Hepatology 13:327–331, 1991.

    Article  Google Scholar 

  23. Schaff Zs and Lapis K: “Recent” forms of hepatitis virus: HCV, HDV, HEV. Orvosképzés 65:287–293, 1990. (in Hungarian only).

    Google Scholar 

  24. Schaff Zs and Lapis K: Hepatitis C virus — The main cause of the non-A, non-B hepatitis. Orv Hetil 131:1903–1906, 1990. (in Hungarian only).

    PubMed  CAS  Google Scholar 

  25. Schvarcz R, Weiland O, Wejstal R, Norkrans G, Fryden A and Foberg U: A randomized, controlled open study of interferon alpha-2b treatment of chronic non-A, non-B posttransfusion hepatitis: no correlation of outcome to presence of hepatitis C virus antibodies. Scand J Infect Dis 21:617–625, 1989.

    Article  PubMed  CAS  Google Scholar 

  26. Shindo M, Di Bisceglie A, Cheung L, Wai-Kuo Shih J, Cristiano K, Feinstone S and Hoofnagle JH: Decrease in serum hepatitis C viral RNA during alpha-interferon therapy for chronic hepatitis C. Ann Intern Med 115:700–704, 1991.

    PubMed  CAS  Google Scholar 

  27. Tine F, Magrin S, Craxi A and Pagliaro L: Interferon for non-A non-B chronic hepatitis. A meta-analysis of randomized clinical trials. J Hepatol 13:192–199, 1991.

    Article  PubMed  CAS  Google Scholar 

  28. Yamada G, Takatani M, Kishi F Takahashi M, Doi T, Tsuji T, Shin S, Tanno M, Urdea MS and Kolberg JA: Efficacy of interferon alfa therapy in chronic hepatitis C patients depends primarily on hepatitis C virus RNA level. Hepatology 22:1351–1354. 1995.

    PubMed  CAS  Google Scholar 

  29. Yoshioka K, Kakumu S, Wakita F, Ishikawa T, Itoh Y, Takayanagi M, Higashi Y, Shibata M and Morishima T: Detection of hepatitis C virus by polymerase chain reaction and response to interferon alpha therapy: relationship to genotypes of hepatitis C virus. Hepatology 16:293–299, 1992.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. 1st Departement of Medicine, Central Hospital of the Ministry of the Interior, Budakeszi út 48/b, 1121, Budapest, Hungary

    Gábor Horváth, Gyula Tolvaj, Henrik Osztrogonácz & Károly Dávid

  2. Department of Pathology, Central Hospital of the Ministry of the Interior, Budapest, Hungary

    Gyula Stotz

Authors
  1. Gábor Horváth
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gyula Stotz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gyula Tolvaj
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Henrik Osztrogonácz
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Károly Dávid
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

This work was supported by the Hungarian Ministry of Welfare (No. T-10 064/93).

Rights and permissions

Reprints and permissions

About this article

Cite this article

Horváth, G., Stotz, G., Tolvaj, G. et al. The effect of long term and high dose interferon treatment in Chronic hepatitis C. Pathol. Oncol. Res. 2, 59–62 (1996). https://doi.org/10.1007/BF02893951

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02893951

Key words

Search

Navigation